PSB202 / Sound Biologics - LARVOL DELTA

NEW DRUG DEVELOPMENT IN LYMPHOMA OF CHINA IS GOING GLOBAL (ICML 2023) - "In two phase 3 head-to-head trials against ibrutinib, Zanubrutinib showed superior ORR and PFS in R/R CLL/SLLpatients, and deeper durable responses in WM patients. Of note, Zanubrutinib plus obinutuzumab was associated with improved PFS compared with obinutuzumab alone in R/R FL acccording to the ROSEWOOD trial. Moreover, Zanubrutinib plus rituximab versus bendamustine plus rituximab is undergoing Phase III trial in transplant-ineligible, untreated MCL...The new BCL-2 inhibitor lisaftoclax (APG-2575) has shown high activity and favorable security as monotherapy and in combination with rituximab or acalabrutinib in patients with treatment-naïve, R/R CLL/SLL from a phase 2 global study. PSB202 is the first-in-class bifunctional antibody that target CD20 and CD37 for the treatment of BCL...In addition to BCL, a phase I/II study demonstrates the antitumor activity and managable safety of Golidocitinib, a selective JAK1 inhibitor, in R/R PTCL. From participation to..."

Clinical • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

Development of PSB202, a bifunctional antibody pair that target CD20 and CD37, for the treatment of B-cell malignancies (AACR 2022) - P1a/1b | "Systemic depletion of normal and malignant B-cells by anti-CD20 antibodies (e.g. rituximab and obinutuzumab) and anti-CD37 antibodies (e.g. otlertuzumab and BI 836826) has been well tolerated in clinical studies...Synergy was demonstrated for PSB202 in combination with lenalidomide...PSB202 offers the potential to improve clinical efficacy, decrease drug resistance, provide administration convenience especially when combining with additional therapeutics, lower the cost for treatment, and reduce the unwanted side effects from chemotherapy. PSB202 is currently being evaluated in patients with previously treated, relapsed, indolent B-cell malignancies (NCT05003141)."

Chronic Lymphocytic Leukemia • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (clinicaltrials.gov) - P1a/1b | N=110 | Recruiting | Sponsor: Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia • CD20

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (clinicaltrials.gov) - P1a/1b; N=110; Not yet recruiting; Sponsor: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

New P1 trial • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia • CD20